Risk factors and outcome of expanded-criteria donor kidney transplants in patients with low immunological risk

Swiss Medical Weekly

Volumn 143, Issue , 2013, Pages

  Praehauser, Claudia ^a   Hirt Minkowski, Patricia ^a   Bakar, Kiymet Saydam ^a   Amico, Patrizia ^a   Vogler, Eliane ^a   Schaub, Stefan ^a   Mayr, Michael ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Deceased kidney donor; Expanded criteria donor; HLA DSA, immunosuppression; Tacrolimus

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CREATININE; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; HLA ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; ANTIBODY; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; AGING; ANTIBODY SPECIFICITY; ARTICLE; COLD ISCHEMIA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DELAYED GRAFT FUNCTION; EXPANDED CRITERIA KIDNEY DONOR; FEMALE; GRAFT FAILURE; GRAFT PRESERVATION; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STANDARD; SURVIVAL RATE; COHORT ANALYSIS; COMPARATIVE STUDY; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIBODIES; COHORT STUDIES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84887918216     PISSN: 14247860     EISSN: 14243997     Source Type: Journal    
DOI: 10.4414/smw.2013.13883     Document Type: Article

References (54)

1. Wynn JJ, Alexander CE. Increasing organ donation and transplantation: the U.S. experience over the past decade. Transpl Int. 2011;24(4):324-32.
2. Wolfe RA, Merion RM, Roys EC, Port FK. Trends in organ donation and transplantation in the United States, 1998-2007. Am J Transplant. 2009;9(4 Pt 2):869-78.
3. Ojo AO, Hanson JA, Meier-Kriesche H, et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol. 2001;12(3):589-97. (Pubitemid 32180029)
4. Port FK, Bragg-Gresham JL, Metzger RA, et al. Donor characteristics associated with reduced graft survival: an approach to expanding the pool of kidney donors. Transplantation. 2002;74(9):1281-6. (Pubitemid 35402598)
5. Rosengard BR, Feng S, Alfrey EJ, et al. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. Am J Transplant. 2002;2(8):701-11. (Pubitemid 36342613)
6. OPTN/SRTR 2009 Annual Report, available at http://optn.transplant.hrsa. gov/ar2009, accessed on 27.5.2011
7. Pascual J, Zamora J, Pirsch JD. A systematic review of kidney transplantation from expanded criteria donors. Am J Kidney Dis. 2008;52(3):553-86.
8. Nyberg SL, Matas AJ, Kremers WK, et al. Improved scoring system to assess adult donors for cadaver renal transplantation. Am J Transplant. 2003;3(6):715-21. (Pubitemid 36745244)
9. Anglicheau D, Loupy A, Lefaucheur C, et al. A simple clinico- histopathological composite scoring system is highly predictive of graft outcomes in marginal donors. Am J Transplant. 2008;8(11):2325-34.
10. Rao PS, Schaubel DE, Guidinger MK, et al. A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index. Transplantation. 2009;88(2):231-6.
11. Schold JD, Kaplan B, Baliga RS, Meier-Kriesche HU. The broad spectrum of quality in deceased donor kidneys. Am J Transplant. 2005;5(4 Pt 1):757-65. (Pubitemid 40461285)
12. Nyberg SL, Baskin-Bey ES, Kremers W, Prieto M, Henry ML, Stegall MD. Improving the prediction of donor kidney quality: deceased donor score and resistive indices. Transplantation. 2005;80(7):925-9. (Pubitemid 41552888)
13. Diet C, Audard V, Roudot-Thoraval F, Matignon M, Lang P, Grimbert P. Immunological risk in recipients of kidney transplants from extended criteria donors. Nephrol Dial Transplant. 2010;25(8):2745-53.
14. Domagala P, Kwiatkowski A, Perkowska-Ptasinska A, et al. Assessment of kidneys procured from expanded criteria donors before transplantation. Transplant Proc. 2009;41(8):2966-9.
15. Remuzzi G, Cravedi P, Perna A, et al. Long-term outcome of renal transplantation from older donors. N Engl J Med. 2006;354(4):343-52. (Pubitemid 43145059)
16. Gallego Valcarce E, Ortega Cerrato A, Llamas Fuentes F, et al. Short cold ischaemia time optimises transplant results for kidneys from expanded criteria donors. Nefrologia. 2009;29(5):456-63.
17. Galeano C, Marcen R, Jimenez S, et al. Utilization of elderly kidney donors (>70 years) does not affect graft survival in the medium term. Transplant Proc. 2010;42(10):3935-7.
18. Metzger RA, Delmonico FL, Feng S, Port FK, Wynn JJ, Merion RM. Expanded criteria donors for kidney transplantation. Am J Transplant. 2003;3(Suppl 4):114-25. (Pubitemid 36612389)
19. Collini A, De Bartolomeis C, Ruggieri G, Barni R, Bernini M, Carmellini M. Long-term outcome of renal transplantation from marginal donors. Transplant Proc. 2006;38(10):3398-9. (Pubitemid 44908442)
20. Goldberg RJ, Smits G, Wiseman AC. Long-term impact of donorrecipient size mismatching in deceased donor kidney transplantation and in expanded criteria donor recipients. Transplantation. 2010;90(8):867-74.
21. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002;346(8):580-90. (Pubitemid 34438820)
22. Stratta RJ, Rohr MS, Sundberg AK, et al. Increased kidney transplantation utilizing expanded criteria deceased organ donors with results comparable to standard criteria donor transplant. Ann Surg. 2004;239(5):688-95; discussion 695-687.
23. Chavalitdhamrong D, Gill J, Takemoto S, et al. Patient and graft outcomes from deceased kidney donors age 70 years and older: an analysis of the Organ Procurement Transplant Network/United Network of Organ Sharing database. Transplantation. 2008;85(11):1573-9.
24. Tullius SG, Tran H, Guleria I, Malek SK, Tilney NL, Milford E. The combination of donor and recipient age is critical in determining host immunoresponsiveness and renal transplant outcome. Ann Surg. 2010;252(4):662-74.
25. Amico P, Honger G, Steiger J, Schaub S. Utility of the virtual crossmatch in solid organ transplantation. Curr Opin Organ Transplant. 2009;14(6):656-61.
26. Dunn TB, Noreen H, Gillingham K, et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant. 2011;11(10):2132-2143.
27. Laperrousaz S, Tiercy S, Villard J, Ferrari-Lacraz S. HLA and non- HLA polymorphisms in renal transplantation. Swiss Med Wkly. 2012;142:w13668.
28. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010;21(8):1398-406.
29. Amico P, Hirt-Minkowski P, Honger G, et al. Risk stratification by the virtual crossmatch: a prospective study in 233 renal transplantations. Transpl Int. 2011.
30. Amico P, Honger G, Mayr M, Steiger J, Hopfer H, Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation. 2009;87(11):1681-8.
31. Patel AM, Pancoska C, Mulgaonkar S, Weng FL. Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant. 2007;7(10):2371-7. (Pubitemid 47347867)
32. Otten HG, Verhaar MC, Borst HP, Hene RJ, van Zuilen AD. Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant. 2012;12(6):1618-23.
33. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
34. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant. 2010;10(3):464-71.
35. Hirt-Minkowski P, Amico P, Honger G, et al. Delayed graft function is not associated with an increased incidence of renal allograft rejection. Clin Transplant. 2012;26(6):E624-633.
36. Stallone G, Infante B, Gesualdo L. Older donors and older recipients in kidney transplantation. Journal of nephrology. 2010;23(Suppl 15):S98-103.
37. Segoloni GP, Messina M, Squiccimarro G, et al. Preferential allocation of marginal kidney allografts to elderly recipients combined with modified immunosuppression gives good results. Transplantation. 2005;80(7):953-8. (Pubitemid 41552892)
38. Srinivas TR, Schold JD, Guerra G, Eagan A, Bucci CM, Meier-Kriesche HU. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant. 2007;7(3):586-94. (Pubitemid 46376441)
39. Gonwa T, Johnson C, Ahsan N, et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation. 2003;75(12):2048-53. (Pubitemid 36793291)
40. Mucha K, Foroncewicz B, Paczek L, et al. 36-month follow-up of 75 renal allograft recipients treated with steroids, tacrolimus, and azathioprine or mycophenolate mofetil. Transplant Proc. 2003;35(6):2176-8. (Pubitemid 37194356)
41. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25):2562-75. (Pubitemid 350294223)
42. Wlodarczyk Z, Walaszewski J, Perner F, et al. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients. Ann Transplant. 2002;7(3):28-31.
43. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant. 2009;9(8):1876-85.
44. Lee JP, Heo NJ, Joo KW, et al. Risk factors for consequent kidney impairment and differential impact of liver transplantation on renal function. Nephrol Dial Transplant. 2010;25(8):2772-85.
45. de Fijter JW. The impact of age on rejection in kidney transplantation. Drugs & aging. 2005;22(5):433-49.
46. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349(24):2326-33. (Pubitemid 37509740)
47. Chapman JR. Chronic calcineurin inhibitor nephrotoxicity-lest we forget. Am J Transplant. 2011;11(4):693-7.
48. Pankewycz O, Leca N, Kohli R, et al. Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study. Transplant Proc. 2011;43(2):519-23.
49. Stegall MD, Park WD, Larson TS, et al. The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant. 2011;11(4):698-707.
50. Kayler LK, Magliocca J, Zendejas I, Srinivas TR, Schold JD. Impact of cold ischemia time on graft survival among ECD transplant recipients: a paired kidney analysis. Am J Transplant. 2011;11(12):2647-56.
51. Gupta A, Iveson V, Varagunam M, Bodger S, Sinnott P, Thuraisingham RC. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant? Transplantation. 2008;85(8):1200-4. (Pubitemid 351590199)
52. van den Berg-Loonen EM, Billen EV, Voorter CE, et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation. 2008;85(8):1086-90. (Pubitemid 351590184)
53. Bielmann D, Honger G, Lutz D, Mihatsch MJ, Steiger J, Schaub S. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant. 2007;7(3):626-32. (Pubitemid 46376450)
54. Heldal K, Thorarinsdottir S, Hartmann A, et al. Induction with inter-leukin- 2 antagonist for transplantation of kidneys from older deceased donors: an observational study. Transplantation research. 2013;2(1):11.